You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Advanced Age-Related Macular Degeneration: Assessment, Strategies, and New Therapies

  • Authors: Jordi Monés, MD, PhD; Jennifer Arnold, MBBS, FRANZCO; Giovanni Staurenghi, MD
  • CPD Released: 6/17/2022
  • Valid for credit through: 6/17/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US physicians caring for patients with advanced AMD, including ophthalmologists, optometrists, and primary care physicians.

The goal of this activity is that learners will be better able to identify and characterize patients with advanced atrophic AMD, including identifying patients who may benefit from emerging treatment in the future, and be better able to understand and interpret latest clinical data on emerging therapies for advanced atrophic AMD.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Classification of Atrophy Meetings (CAM) consensus guidelines on assessment of patients with advanced atrophic AMD using optical coherence tomography
    • Identification of patients with advanced atrophic AMD at risk of fast progression
    • Latest clinical data on emerging therapies for geographic atrophy secondary to AMD


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Jordi Monés, MD, PhD

    Opthalmologist, Macula and Vitreoretinal Specialist
    Director, Institut de la Màcula
    Director, Barcelona Macula Foundation
    Barcelona, Spain

    Disclosures

    Jordi Monés, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: Alexion; Apellis; Cellcure; Ionis Pharmaceuticals; Iveric Bio; Kodiak Sciences; Lineage Cell Therapetuics; Maculogix;  Novartis; Reneuron; Roche
    Research funding from: Apellis; Ionis Pharmaceuticals; Iveric Bio; Kodiak Sciences; Novartis; Reneuron; Roche
    Contracted researcher for: Apellis; Ionis Pharmaceuticals; Iveric Bio; Kodiak Sciences; Novartis; Reneuron; Roche
    Speaker or member of speakers bureau for: Apellis; Cellcure; Iveric Bio; Lineage Cell Therapeutics; Maculogix; Novartis; Reneuron; Roche
    Stock options from: Iveric Bio; Notalvision

  • Jennifer Arnold, MBBS, FRANZCO

    Director and Principal Investigator
    Retina at Marsden Eye Research
    Marsden Eye Specialists
    Sydney, Australia

    Disclosures

    Jennifer Arnold, MBBS, FRANZCO, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie; Allergan; Apellis; Bayer; Novartis; Roche
    Speaker or member of speakers bureau for: AbbVie; Allergan; Apellis; Bayer; Novartis; Roche
    Research funding from: Apellis; Bayer; Ionis Ophthea; Genentech; Roche; Sandoz

  • Giovanni Staurenghi, MD

    Professor of Ophthalmology
    University of Milan
    Milan, Italy 

    Disclosures

    Giovanni Staurenghi, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Allergan; Apellis; Astellas; Bayer; Boehringer Ingelheim; Carl Zeiss Meditec; Centervue; Chengdu Kanghong Biotechnology Co; Genentech; Graybug; Heidelberg Engineering; Iveric; Kyoto Drug Discovery & Development Co; Novartis; Optos; Roche 
    Speaker or member of speakers bureau for: Allergan; Apellis; Bayer; Genentech; Heidelberg Engineering; Novartis; Optos; Roche
    Research funding from: Allergan; Bayer; Boehringer Ingelheim; Carl Zeiss Meditec; Centervue; Genentech; Heidelberg Engineering; Novartis; Optos; Optovue; Quantel Medical; Roche; Topcon
    Royalties from: Ocular Instruments

Editor

  • Katherine Carpenter, PhD

    Medical Education Director, WebMD Global, LLC 

    Disclosures

    Katherine Carpenter, PhD has the following relevant financial relationships: 
    Advisor or consultant for: Eisai, GW Pharmaceuticals (former)

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Advanced Age-Related Macular Degeneration: Assessment, Strategies, and New Therapies

Authors: Jordi Monés, MD, PhD; Jennifer Arnold, MBBS, FRANZCO; Giovanni Staurenghi, MDFaculty and Disclosures

CPD Released: 6/17/2022

Valid for credit through: 6/17/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to identify and characterize patients with advanced atrophic AMD, including identifying patients who may benefit from emerging treatment in the future, and be better able to understand and interpret latest clinical data on emerging therapies for advanced atrophic AMD.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print